Roche’s Tecentriq snags FDA label expansion in type of colon cancer - Pharmaceutical Technology

Tecentriq is now the first immunotherapy indicated for dMMR colon cancer specifically, which is often linked to a higher risk of progression after surgery. Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher risk of progression after surgery. Tecentriq is now approved across 12 cancer indications. Credit: Jo Panuwat D / Shutterstock.com. Roche has notched a twelfth indication on the belt of its blockbuster cancer therapy Tecentriq (atezolizumab), following the US Food and Drug Administration’s (FDA) decision to approve the drug in a subset of patients with colon cancer.…

Source: Pharmaceutical Technology